Medical network on April 21 - according to flush data statistics, as of April 18, a total of 12 pharmaceutical shares the latest market capitalisation in 40 billion yuan of above, latest hengrui pharmaceutical market capitalisation topped, reached 129.016 billion yuan, Shanghai pharmaceutical and sig alex's latest total market value are more than 90 billion yuan, respectively, 99.852 billion yuan and 92.414 billion yuan, in addition, the latest market capitalisation in 40 billion yuan of above pharmaceutical stocks are: yunnan baiyao (89.383 billion yuan), fosun medicine (70.706 billion yuan), Shanghai pharmaceutical (59.274 billion yuan), step length (55.649 billion yuan), east China pharmaceutical (45.218 billion yuan), baiyun mountain (44.074 billion yuan), tongrentang (43.585 billion yuan), tasly (43.446 billion yuan), the company (42.655 billion yuan). 

 

 

 

Of these stocks except no agencies step pharmaceutical, 11 other stocks generally by institutions, the recent one month, tasly (15), Shanghai pharmaceutical (12), east China pharmaceutical (10) and other three stock agency favors rating number in 10 and above, hengrui pharmaceutical, fosun medicine, individual institutions, such as the company to "buy" or "overweight" rating number are also in more than five. 

 

It is worth mentioning that Shanghai alex, sig pharmaceutical, yunnan baiyao and fosun pharma stocks are generally recognized market is expected to hit one hundred billion yuan, huatai securities said bullish on sig pharmaceutical as yinpian leading companies benefit from the industry booming, hospital layout speed drive pharmaceutical trade volume, traditional Chinese medicine trade under the stimulus price rebound face upward cycle, estimated 2017, 2018 net income of 4.2 billion yuan, 4.2 billion yuan, corresponding to earnings per share 0.84 yuan, 1.02 yuan, to give 2017 p/e ratio of 25 to 30 times, highest target price to $25, for the first time to "overweight" rating. Once the sig pharmaceutical latest closing price reach agency predicted target price, the total value will exceed one hundred billion yuan to 123.681 billion yuan. 

 

And in addition to the big stock market value this feature generally endorsed, reasonable valuations, strong growth performance uncertainty has become a part of the funds in the short-term optimization pharmaceutical shares important indicators, the above by institutions of 11 large-cap stocks latest p/e ratio is below the industry average (87.53 times), Shanghai latest alex's dynamic price-earnings ratio of 61.9 times, highest performance, combined with 2016 annual report and a quarterly in 2017, the 9 of 11 companies companies have disclosed in 2016 annual report, except the tasly 2016 net profit year-on-year must decline, other companies are to realize rose, while tasly net profit year-on-year growth of 14.84% in the first quarter, the company's performance bottoming out in the future is expected to become stable growth include societe generale securities, China international capital corporation, southwest securities institutions, such as consensus.